Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Man Group plc

Man Group plc increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 87.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 199,304 shares of the medical equipment provider's stock after acquiring an additional 92,701 shares during the quarter. Man Group plc owned approximately 0.29% of Lantheus worth $17,830,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of LNTH. Mirae Asset Global Investments Co. Ltd. raised its stake in Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock valued at $1,041,000 after buying an additional 3,772 shares in the last quarter. Empirical Asset Management LLC acquired a new stake in Lantheus during the fourth quarter valued at approximately $323,000. Focus Financial Network Inc. acquired a new stake in Lantheus during the fourth quarter valued at approximately $292,000. Janney Montgomery Scott LLC raised its stake in Lantheus by 40.9% during the fourth quarter. Janney Montgomery Scott LLC now owns 19,806 shares of the medical equipment provider's stock valued at $1,772,000 after buying an additional 5,753 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in Lantheus by 31.7% during the fourth quarter. Van ECK Associates Corp now owns 76,996 shares of the medical equipment provider's stock valued at $6,888,000 after buying an additional 18,524 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Activity

In related news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,109 shares of company stock valued at $6,016,046. 1.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Truist Financial cut their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, B. Riley cut their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $132.67.

Lantheus Trading Up 1.8%

NASDAQ:LNTH opened at $81.24 on Friday. The firm has a market capitalization of $5.56 billion, a PE ratio of 13.52 and a beta of 0.23. The stock has a 50 day moving average of $97.11 and a 200-day moving average of $93.31. Lantheus Holdings, Inc. has a 52 week low of $75.00 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm's revenue for the quarter was up .8% compared to the same quarter last year. During the same period last year, the company posted $1.69 earnings per share. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.